Fulgent Genetics (NASDAQ:FLGT) specializes in comprehensive genetic testing and next-generation sequencing solutions, catering to both individuals and healthcare providers. This company leverages advanced technologies and a vast gene database to offer an extensive range of genetic screening and testing services aiming at improving disease diagnosis, treatments, and preventative healthcare measures. Fulgent Genetics is committed to expanding its portfolio of genetic tests, enhancing the accuracy and accessibility of personalized medicine, and continuously invests in research and development to stay at the forefront of genomic diagnostics. Its objectives include making genetic testing more affordable, broadening its test offerings, and extending its global reach to impact patient care worldwide.